Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of rebeccamycin analog and
oxaliplatin in treating patients with refractory solid tumors. Drugs used in chemotherapy,
such as rebeccamycin analog and oxaliplatin, work in different ways to stop tumor cells from
dividing so they stop growing or die. Combining more than one drug may kill more tumor cells